Stage IV Bladder Cancer Clinical Trial
Official title:
A Phase II Safety and Efficacy Study With the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients With Metastatic Urothelial Cancer
This phase II trial is studying the side effects and how well pazopanib works in treating patients with metastatic urothelial cancer. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Status | Completed |
Enrollment | 19 |
Est. completion date | December 2013 |
Est. primary completion date | July 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed transitional cell cancer of the urothelium or bladder - Metastatic disease - Measurable disease, defined as = 1 unidimensionally measurable lesion = 2.0 cm by conventional techniques OR = 1.0 cm by spiral CT scan - No known brain metastases - ECOG performance status 0-2 - Life expectancy = 12 weeks - Platelet count = 100,000/mm^3 - WBC = 3,000/mm^3 - Absolute neutrophil count = 1,500/mm^3 - Bilirubin normal - AST and ALT = 2.5 times upper limit of normal (ULN) - Creatinine normal OR creatinine clearance = 60 mL/min - PT/INR/PTT = 1.2 times ULN - No proteinuria > 1+ on two consecutive dipsticks measured = 1 week apart - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or other agents used in the study - No condition that impairs the ability to swallow and retain pazopanib hydrochloride tablets, including any of the following: - Gastrointestinal tract disease resulting in an inability to take oral medication - Requirement for IV alimentation - Prior surgical procedures affecting absorption - Active peptic ulcer disease - No uncontrolled illness that would limit compliance with study therapy including, but not limited to, any of the following: - Ongoing or active infection - Psychiatric illness or social situations - No QTc prolongation (defined as a QTc interval = 480 msecs) or other significant ECG abnormalities (e.g., frequent ventricular ectopy, evidence of ongoing myocardial ischemia) - No other conditions, including any of the following: - Serious or non-healing wound, ulcer, or bone fracture - Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days - Cerebrovascular accident within the past 6 months - Myocardial infarction, cardiac arrhythmia, or admission for unstable angina within the past 12 weeks - Venous thrombosis within the past 12 weeks - New York Heart Association (NYHA) class III or IV heart failure - Asymptomatic NYHA class II heart failure on treatment allowed - No other active second malignancy other than non-melanoma skin cancer - Patients are not considered to have an active malignancy if they have completed anti-cancer therapy and are considered by their physician to be = 30% risk of relapse - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered - At least 4 weeks since prior radiotherapy - Prior palliative radiotherapy to metastatic lesions allowed provided there is = 1 measurable and/or evaluable lesion(s) that has not been irradiated - At least 4 weeks since prior surgery - One prior chemotherapy regimen for metastatic urothelial or bladder cancer - More than 12 weeks since prior cardiac angioplasty or stenting - Prior adjuvant or neoadjuvant therapy allowed - No prior experimental treatment for metastatic disease - No other prior or concurrent investigational agents - No concurrent combination antiretroviral therapy for HIV-positive patients - No concurrent CYP2C9 substrates, including any of the following: - Anticoagulants (e.g., warfarin [therapeutic doses only]) - Low molecular weight heparin and prophylactic low-dose warfarin (= 2 mg daily) allowed - Oral hypoglycemics (e.g., glipizide, glyburide, tolbutamide, glimepiride, or nateglinide) - Ergot derivatives (e.g., dihydroergotamine, ergonovine, ergotamine, or methylergonovine) - Antipsychotics (e.g., pimozide or clozapine) - Erectile dysfunction agents (e.g., sildenafil, tadalafil, or vardenafil) - Antiarrhythmics (e.g., bepridil, flecainide, lidocaine, mexiletine, amiodarone, quinidine, or propafenone) - Immune modulators (e.g., cyclosporine, tacrolimus, or sirolimus) - Miscellaneous drugs (e.g., theophylline, quetiapine, risperidone, tacrine, or atomoxetine) - No other concurrent anticancer agents or therapies - No concurrent medications that are associated with a risk of QTc prolongation and/or Torsades de Pointes |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Chinese University of Hong Kong-Prince of Wales Hospital | Shatin | Hong Kong |
Korea, Republic of | Gangnam Severance Hospital | Seoul | |
United States | Johns Hopkins University | Baltimore | Maryland |
United States | Wayne State University | Detroit | Michigan |
United States | Mayo Clinic in Florida | Jacksonville | Florida |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Metro-Minnesota CCOP | Saint Louis Park | Minnesota |
United States | Cox Medical Center | Springfield | Missouri |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States, China, Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) | Tumor response is defined as the total number of eligible patients whose disease has a complete or partial response to GW786034 according to the RECIST criteria. Per RECIST v1.0 criteria: A Complete Response (CR) requires the disappearance of all target lesions. A Partial Response (PR) requires >=30% decrease in the sum of the longest diameter of target lesions from baseline measurement. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response. |
Participants will be evaluated every 8 weeks during treatment and up to 1 year after completion of treatment. | No |
Secondary | Adverse Events Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 | The maximum grade for each adverse event considered to be at least possibly related to treatment will be recorded. Frequency tables will be constructed. | Every 4 weeks during treatment (maximum duration was 44 weeks) | Yes |
Secondary | Confirmed Tumor Response (CR and PR) | Tumor response is defined as the total number of eligible patients whose disease has a complete or partial response to GW786034 according to the RECIST criteria. A confirmed response is defined as a CR or PR and is documented on 2 consecutive evaluations. | Documented on 2 consecutive evaluations 8 weeks apart from the start of the treatment until disease progression/recurrence, assessed up to 1 year | No |
Secondary | Duration of Response | The distribution of response durations will be estimated using the Kaplan-Meier method. | From the time an objective response is first noted to be either a CR or PR to the date progression is documented, assessed up to 1 year | No |
Secondary | Time to Disease Progression | The distribution of progression-free survival times will be estimated using the Kaplan-Meier method. | Every 3 months from registration until progressive disease (PD), assessed up to 2 years after registration | No |
Secondary | Survival Time | The distribution of survival times will be estimated using the Kaplan-Meier method. | Time from registration until death due to any cause, assessed every 6 months after PD for up to 2 years after registration | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02122172 -
Afatinib in Advanced Refractory Urothelial Cancer
|
Phase 2 | |
Completed |
NCT03229278 -
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
|
Phase 1 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01938573 -
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT00112905 -
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
|
Phase 2 | |
Terminated |
NCT00072137 -
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
|
Phase 1 | |
Completed |
NCT00072150 -
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00028756 -
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
|
Phase 3 | |
Completed |
NCT00407485 -
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
|
Phase 2 | |
Terminated |
NCT00003452 -
Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder
|
Phase 2 | |
Completed |
NCT00003167 -
Gene Therapy in Treating Patients With Advanced Bladder Cancer
|
Phase 1 | |
Completed |
NCT00005831 -
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
|
Phase 2 | |
Completed |
NCT00021099 -
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
|
Phase 2 | |
Terminated |
NCT01382706 -
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
|
Phase 2 | |
Active, not recruiting |
NCT04267575 -
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
|
N/A | |
Terminated |
NCT01954173 -
Adjuvant Radiation for High Risk Bladder Cancer
|
N/A | |
Terminated |
NCT00004856 -
Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium
|
Phase 2 | |
Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
Terminated |
NCT01282333 -
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01828736 -
Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma
|
Phase 2 |